Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 1, 2007, Pages 123-132

  Pandyra, Aleksandra A ^a   Berg, Randal ^a,b   Vincent, Mark ^a,b,c   Koropatnick, James ^a,b,c  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN BCL 2; SMALL INTERFERING RNA; THYMIDYLATE SYNTHASE;

ARTICLE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA SEQUENCE;

CELL LINE, TUMOR; CELL PROLIFERATION; FLOXURIDINE; G1 PHASE; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINAZOLINES; RNA, MESSENGER; RNA, SMALL INTERFERING; TAXOIDS; THIOPHENES; THYMIDYLATE SYNTHASE;

EID: 34250693622     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.115394     Document Type: Article

References (32)

1. Basma H, El-Refaey H, Sgagias MK, Cowan KH, Luo X, and Cheng PW (2005) BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53. J Biomed Sci 12:999-1011.
2. Bélanger S, Cote M, Lane D, L'Esperance S, Rancourt C, and Piche A (2005) Bcl-2 decreases cell proliferation and promotes accumulation of cells in S phase without affecting the rate of apoptosis in human ovarian carcinoma cells. Gynecol Oncol 97:796-806.
3. Berg RW, Ferguson PJ, Vincent MD, and Koropatnick DJ (2003) A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance. Cancer Gene Ther 10:278-286.
4. 2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase. J Pharmacol Exp Ther 298:477-484.
5. Biroccio A, Leonetti C, and Zupi G (2003) The future of antisense therapy: combination with anticancer treatments. Oncogene 22:6579-6588.
6. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, and Borden EC (2004) Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11:915-923.
7. Chu E and Allegra CJ (1996) The role of thymidylate synthase as an RNA binding protein. Bioessays 18:191-198.
8. Cioca DP, Aoki Y, and Kiyosawa K (2003) RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther 10:125-133.
9. Costi MP, Ferrari S, Venturelli A, Calo S, Tondi D, and Barlocco D (2005) Thymidylate synthase structure, function and implication in drug discovery. Curr Med Chem 12:2241-2258.
10. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, and Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.
11. Elez R, Piper A, Kronenberger B, Kock M, Brendel M, Hermann E, Pliquett U, Neumann E, and Zeuzem S (2003) Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene 22:69-80.
12. Farrugia DC, Ford HE, Cunningham D, Danenberg KD, Danenberg PV, Brabender J, McVicar AD, Aherne GW, Hardcastle A, McCarthy K, et al. (2003) Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res 9:792-801.
13. Ferguson PJ, Collins O, Dean NM, DeMoor J, Li CS, Vincent MD, and Koropatnick J (1999) Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol 127:1777-1786.
14. Ferguson PJ, DeMoor JM, Vincent MD, and Koropatnick J (2001) Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells. Br J Pharmacol 134:1437-1446.
15. Fisher TC, Milner AE, Gregory CD, Jackman AL, Aherne GW, Hartley JA, Dive C, and Hickman JA (1993) bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 53:3321-3326.
16. Flaherty KT, Stevenson JP, and O'Dwyer PJ (2001) Antisense therapeutics: lessons from early clinical trials. Curr Opin Oncol 13:499-505.
17. Flynn J, Berg RW, Wong T, van Aken M, Vincent MD, Fukushima M, and Koropatnick J (2006) Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma. Mol Cancer Ther 5:1423-1433.
18. Gleave ME and Monia BP (2005) Antisense therapy for cancer. Nat Rev Cancer 5:468-479.
19. Houghton JA, Harwood FG, and Tillman DM (1997) Thymineless death in colon carcinoma cells is mediated via fas signaling. Proc Natl Acad Sci U S A 94:8144-8149.
20. Huang DC, O'Reilly LA, Strasser A, and Cory S (1997) The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 16:4628-4638.
21. Izquierdo M (2005) Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther 12:217-227.
22. Jiang SX, Sato Y, Kuwao S, and Kameya T (1995) Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 177:135-138.
23. Johnson KR, Young KK, and Fan W (1999) Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy. Clin Cancer Res 5:2559-2565.
24. Lima RT, Martins LM, Guimaraes JE, Sambade C, and Vasconcelos MH (2004) Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 11: 309-316.
25. Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG, Herold C, and Schuppan D (2005) Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut 54:1298-1308.
26. Schmitz JC, Chen TM, and Chu E (2004) Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds. Cancer Res 64:1431-1435.
27. Shore GC and Viallet J (2005) Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematol Am Soc Hematol Educ Program 2005:226-230.
28. Sup SJ, Alemany CA, Pohlman B, Elson P, Malhi S, Thakkar S, Steinle R, and Hsi ED (2005) Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol 23:3773-3779.
29. Tafech A, Bassett T, Sparanese D, and Lee CH (2006) Destroying RNA as a therapeutic approach. Curr Med Chem 13:863-881.
30. Tanabe K, Kim R, Inoue H, Emi M, Uchida Y, and Toge T (2003) Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Int J Oncol 22:875-881.
31. Vairo G, Soos TJ, Upton TM, Zalvide J, DeCaprio JA, Ewen ME, Koff A, and Adams JM (2000) Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation. Mol Cell Biol 20:4745-4753.
32. Yawata A, Kim SR, Miyajima A, Kubo T, Ishida S, Saito Y, Nakajima Y, Katori N, Matsumoto Y, Fukuoka M, et al. (2005) Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents. Cancer Chemother Pharmacol 56:465-472.